Imagion Biosystems has announced the successful completion of the renounceable rights issue raising approximately $3.6 million.
Read Imagion Biosystems’ Right Issue raises $3.6 million.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance